Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain

Abstract

Bicifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) inhibits monoamine neurotransmitter uptake by recombinant human transporters in vitro with a relative potency of norepinephrine Ͼ serotonin Ͼ dopamine (Ϸ1:2:17). This in vitro profile is supported by microdialysis studies in freely moving rats, where bicifadine (20 mg/kg i.p.) increased extrasynaptic norepinephrine and serotonin levels in the prefrontal cortex, norepinephrine levels in the locus coeruleus, and dopamine levels in the striatum. Orally administered bicifadine is an effective antinociceptive in several models of acute, persistent, and chronic pain. Bicifadine potently suppressed pain responses in both the Randall-Selitto and kaolin models of acute inflammatory pain and in the phenyl-p-quinone-induced and colonic distension models of persistent visceral pain. Unlike many transport inhibitors, bicifadine was potent and completely efficacious in both phases of the formalin test in both rats and mice. Bicifadine also normalized the nociceptive threshold in the complete Freund's adjuvant model of persistent inflammatory pain and suppressed mechanical and thermal hyperalgesia and mechanical allodynia in the spinal nerve ligation model of chronic neuropathic pain. Mechanical hyperalgesia was also reduced by bicifadine in the streptozotocin model of neuropathic pain. Administration of the D 2 receptor antagonist (Ϫ)-sulpiride reduced the effects of bicifadine in the mechanical hyperalgesia assessment in rats with spinal nerve ligations. These results indicate that bicifadine is a functional triple reuptake inhibitor with antinociceptive and antiallodynic activity in acute, persistent, and chronic pain models, with activation of dopaminergic pathways contributing to its antihyperalgesic actions.Multiple neurotransmitters have been implicated in the modulation of nociceptive signaling at both the spinal and supraspinal levels of central nervous system processing (Millan, 2002). Among these, norepinephrine (NE) and serotonin (5-HT) play important roles in modulating nociceptive information via pathways descending from the brainstem to the level of the dorsal horn. Noradrenergic fibers from the locus coeruleus and subcoeruleus descend Article, publication date, and citation information can be found at

Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression

“…The Chung model of neuropathic pain (Kim and Chung, 1992) was performed at Porsolt & Partners Pharmacology as described previously (Basile et al, 2007). In brief, rats were anesthetized with sodium pentobarbital and the left L5 and L6 spinal nerves were ligated, followed by 2 weeks of recovery.…”

SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation

“…11) is a potent inhibitor of SERT and NET and is currently in development against neuropathic pain (Krieter et al, 2008). It is noteworthy that bicifadine also possess inhibitory activity against DAT (Basile et al, 2007), which indicates that inhibition of all three monoamine transporters might provide a novel and efficacious strategy for the treatment of neuropathic pain. Tapentadol [(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol] combines NRI activity with -opioid receptor agonism in a single molecule.…”

Triple Reuptake Inhibitors as Potential Next-Generation Antidepressants: A New Hope?

“…Here, we summarize TRIs that have been pursued to preclinical and investigational stage (Figure 4 & Table 3). DOV 220,075 or 1-(4-methylphenyl)-3-azabicyclo [3.1.0] hexane (Bicifadine) was developed as analgesic and for the treatment of pain by the DOV Pharmaceuticals [103]. It has stronger affinity toward SERT and NET compared with DAT (Table 3).…”